SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from NANOVIRICIDES, INC. (NNVC) (CIK 0001379006) (NNVC) — Apr 10, 2012

NANOVIRICIDES, INC. (NNVC) (CIK 0001379006)
Date: April 10, 2012 · CIK: 0001379006 · Accession: 0001144204-12-020870

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 000-52318

Referenced dates: March 31, 2012

Date
April 9, 2012
Author
/s/ Eugene Seymour, M.D., MPH
Form
CORRESP
Company
NANOVIRICIDES, INC. (NNVC) (CIK 0001379006)

Letter

VIA EDGAR ONLY United States Securities and Exchange Commission Attention: Jim B. Rosenberg, Form 10-K for the Fiscal Year Ended June 30, 2011 Filed October 13, 2011 File No. 000-52318

Re: NanoViricides, Inc.

Dear Mr. Rosenberg,

The purpose of this correspondence is to respectfully request an additional ten day extension to reply to the comments of the staff of the U.S. Securities and Exchange Commission with respect to the above-referenced filings provided in your letter dated March 31, 2012.

Should you have any questions or require any further information, please do not hesitate to contact us.

Very truly yours,
/s/ Eugene Seymour, M.D., MPH

Show Raw Text
CORRESP
1
filename1.htm

April 9, 2012

VIA EDGAR ONLY

United States Securities and Exchange Commission

Mail Stop 4720

Washington, D.C. 20549

    Attention:
    Jim B. Rosenberg,

    Senior Assistant Chief Accountant

        Re: NanoViricides, Inc.

        Form 10-K for the Fiscal Year Ended June 30, 2011

        Filed October 13, 2011

        File No. 000-52318

Dear Mr. Rosenberg,

The purpose of this
correspondence is to respectfully request an additional ten day extension to reply to the comments of the staff of the U.S. Securities
and Exchange Commission with respect to the above-referenced filings provided in your letter dated March 31, 2012.

Should you have any
questions or require any further information, please do not hesitate to contact us.

    Very truly yours,

    /s/ Eugene Seymour, M.D., MPH

    Chief Executive Officer